DENVER–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells. Cannabis Science, in conjunction with Rockbrook, its Colorado-licensed dispensary, consulted with a variety of cancer patients who were seeking to inform themselves of the current peer reviewed scientific literature, regarding the historical use of cannabis to treat “tumors”. Unlike most conventional cancer treatments, cannabis has an outstanding safety profile, and patients in states with medical marijuana laws are able to make an informed decision to legally try various cannabis preparations to determine what is most effective for their particular condition.
Some of these scientifically informed patients have chosen to self-administer Cannabis Science extracts supplied by Rockbrook to treat their own cancers. Cannabis Science is delighted that patients are reporting dramatic improvements in their conditions, including basal cell carcinoma, non-small cell lung cancer accompanied by COPD (chronic obstructive pulmonary disease), ovarian cancer, and glioma.
Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments.
For example, a patient with basal cell carcinoma used a topical formulation to dramatically and rapidly eliminate her obvious skin cancer. Meanwhile, patients with internal tumors used oral formulations for their treatment. We currently await more complete clinical evaluations of the patients’ own reports of dramatic health improvements coincident with tumor shrinkage and disappearance.
Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc., stated, “We will pursue and acquire intra-state generated data to make these cancer medicines available to the public at large as rapidly as possible. To accomplish this goal, we will seek accelerated FDA approval. We are on the verge of a revolution in medicine. Cannabis is now returning to modern medicine for all the right reasons. State generated results give us a unique ability to acquire scientific and clinical data for cannabis-based cancer treatments. As previously announced, we will use our new laboratory facility to house analytical instrumentation, tissue culture, clean rooms and additional necessary equipment. This facility will meet or exceed all federal, state, and local requirements to allow for the necessary for FDA clinical trials.”
Cannabis Science expects to hold a press conference soon to formally announce its cancer formulation progress and future plans for cancer treatments. Brand names for our new cancer treatment drugs are currently being vetted through the company attorney for future commercial use.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
Mark J. Friedman